Tag: Alzheimer’s
Pimavanzserin Cuts Alzheimer’s Psychosis at Six Weeks
Significantly greater reduction in NPI-NH psychosis score at 6 weeks versus placebo, but not at 12 weeks
In Alzheimer’s, BACE1 Inhibition May Reverse Amyloid Deposition
Sequential, increased deletion of BACE1 in adult AD mouse model reversed amyloid deposition
Deep Brain Stimulation May Be Promising Alzheimer’s Treatment
DBS at ventral capsule/ventral striatum linked to less decline on Clinical Dementia Rating-Sum of Boxes
Solanezumab Doesn’t Affect Cognitive Decline in Alzheimer’s
No difference between the drug and placebo in change in ADAS cognitive subscale score at week 80
Idalopirdine May Not Improve Cognition in Mild Alzheimer’s
Findings from three randomized trials show no improvement in cognition vs. placebo over 24 weeks
Memory Scores Limited As Alzheimer’s Screening Tool
Scores are an early marker of amyloid positivity, but limited in value for those without dementia
Magnesium Boosts Environmental Enrichment in Alzheimer’s
Combination of EE, magnesium-L-threonate more effective than either treatment alone in mouse model
Retinal Sensitivity Linked to Cognitive Status in T2DM
Retinal sensitivity assessed by microperimetry is correlated with neurodegeneration parameters
Gender-Specific High-Risk ‘Window’ Seen in Alzheimer’s
Women genetically predisposed to Alzheimer's more susceptible than men from 65 to 75 years of age
Blood Pressure Variability Linked to Risk of Dementia in Elderly
Increased variability risk factor for dementia, vascular dementia, Alzheimer's, independent of BP
